Regression of prostatic hypertrophy by osaterone acetate in dogs.
The prostatic regression effect of oral administration of a new steroidal anti-androgen, osaterone acetate, was investigated in dogs with prostatic hypertrophy. To dogs with prostatic hypertrophy, 0.1-1.0 mg/kg of osaterone acetate was orally administered for one week, and the regression rate was observed. It was shown that administration of osaterone acetate at 0.2 mg/kg or higher, sharply regressed prostatic hypertrophy during the early stage. Therefore, this agent may be clinically applicable as a therapeutic agent for benign prostatic hypertrophy.
Tsutsu
T
T
Department of Reproduction, Nippon Veterinary and Animal Science University, Musashino-shi, Tokyo, Japan.
Hori
T
T
Shimizu
M
M
Orima
H
H
Kawakami
E
E
Fukuda
S
S
D000284:Administration, Oral; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D000818:Animals; D002715:Chlormadinone Acetate / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use*; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000662:veterinary*; D013739:Testosterone / Q000097:blood
D000726:Androgen Antagonists; D002715:Chlormadinone Acetate; D013739:Testosterone; D007986:Luteinizing Hormone; C069297:osaterone acetate